Physician profile
John Petrilli
NPI 1609213016
$724.54
in general payments reported to CMS, 2019-2025
17 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $78.50 · 2024: $202 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $388.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $185.70 | 2019-2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $86.67 | 2024-2025 | |
| Dynavax Technologies Corporation | $49.39 | 2024-2025 | Heplisav-B |
| Exact Sciences Corporation | $47.64 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $44.73 | 2024-2025 | Ozempic, Rybelsus |
| Recor Medical INC | $40.08 | 2024 | Paradise Renal Denervation System |
| Amgen INC. | $37.95 | 2024-2025 | Repatha |
| Glaxosmithkline, LLC. | $31.64 | 2025 | |
| Pfizer INC. | $29.36 | 2019-2020 | |
| Lilly USA, LLC | $27.85 | 2019-2024 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.01 | 2019 | |
| Sunovion Pharmaceuticals INC. | $22.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.26 | 2024 | |
| Mylan Specialty L.P. | $19.46 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.49 | 2020 | |
| Merck Sharp & Dohme LLC | $13.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Petrilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.